Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:

NCT ID: NCT02118090

Last Updated: 2015-03-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 73 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-31
• Study Completion Date: 2015-03-31

Brief Summary

The investigators propose to leverage the unique infrastructures and expertise of National Centre for Parasitology Entomology and Malaria Control and the Pasteur Institute in Cambodia and combine modern fieldwork, including a mobile laboratory fully equipped for molecular biology and culture experiments, with state-of-the-art genomic analyses to investigate how Plasmodium vivax parasites respond to antimalarial drugs. The investigators will focus on resistance to CQ, the choice treatment for vivax malaria in most endemic countries, for which treatment failures have been reported in Cambodia. The study will address some of the key biological mechanisms limiting the efficiency of drug therapy in P. vivax, including the identification of genetic polymorphisms underlying drug resistance in Cambodian P. vivax. The findings will provide a first unbiased perspective on the mechanisms of drug resistance in P. vivax and have the strong potential to significantly improve malaria control in Southeast Asia.

Detailed Description

In order to assess the resistance phenotype of P. vivax to CQ, the methodology will involve the following steps:

1. Inclusion of P.vivax mono-infected patients from villages in treatment failure-reported area (Ban Lung district, Rattanakiri)

2. Pv diagnostic confirmation (microscopy and qPCR)

3. Transfer of patients to Ban Lung hospital for a 7-days clinical follow-up

4. Blood collection followed by CQ administration

5. Parasite clearance and whole blood CQ concentration follow-up during 7 days.

6. Parasitemia follow-up during 2 months with patients staying in Ban Lung during the entire study to make sure no re-infection occurs (Ban Lung is a no-transmission area).

7. Ex vivo drug susceptibility assay of P. vivax isolates and after any recrudescence/relapse, if any.

8. Genotyping analysis of parasites at Day 0 and after any recrudescence/relapse, if any.

Research design

The study will be carried out in Ban Lung district (Rattanakir province, Cambodia) between April 2014 and December 2014. This research site (Rattanakiri) is chosen on the basis of relatively high reports of treatment failures to CQ. In Ban Lung district villages, all P. vivax mono-infected adult patients seeking treatment at community level (VMW and Health centers) will be offered to participate to the study

The sample size calculation was based on addressing the primary objective of identifying a true resistance phenotype to CQ. Therefore a minimum of 50 patients is required and ideally, around 100 patients will increase the probability of detecting resistant parasites.

All eligible participants will be approached by the study staff and information about the objectives of the study will be explained. Informed consent will be obtained from each participant before inclusion.

All P. vivax mono-infected patients identified in the study sites will be included.

Staff involved in this research study will be composed from scientists and technicians from CNM and IPC. Additional collaborators (Reference hospital, Health centers and VMW staff ion Rattanakiri province) will be involved in the project.

Villages in Ban Lung district where P. vivax transmission occur will be selected. Patients seeking treatment from those villages (VMW and Health canters) will be tested for malaria infection by RDT and any non-P. falciparum infected patient will be offered to participate to the study. Falciparum malaria cases will be managed by VMW and Health centers as usually according to Cambodian National guidelines

After obtaining informed consent, the patients will be enrolled in the study and two groups will be constituted:

1. a control group of patients staying in their village and

2. a group transferred to Banlung hospital.

Then, 3 x 5ml-ACD tubes of venous blood will be collected prior to be given CQ to patients.

For the control group, parasitemia will be followed at Day3, D7, D14, D28 and D42 D49, D56 and D60 according to WHO protocol, using fingerprick-collected blood.

For the study group, patients will be followed by fingerprick for parasites clearance and CQ concentration measures every 8h for at least 3 days until complete parasite clearance (determined by two consecutive negative results in microscopy and qPCR). Parasitemia and CQ concentration will be determined daily using fingerprick for 7 days.

To make sure the patients will not be re-infected, they will stay in Ban Lung accommodation for 2 months with every 48h fingerpricks to detect any increase in parasitemia during the study, while the control group will stay in their village where re-infection can occur.

If recrudescence is observed, patients will then be re-admitted in Ban Lung hospital and the same protocol will be performed again.

Ex vivo drug sensitivity assay of the P. vivax isolates will be performed either directly from the blood samples or after cryopreservation. In both case, the assay will involve the invasion of freshly added reticulocytes to the P. vivax isolates.

The reticulocytes used for this work will be obtained from cord blood acquired through the gynecology/obstetric department of Calmette hospital (Pr Kruy Leang Sim), according to the agreement between IPC and Calmette hospital. Cord blood will be supplied regularly to IPC, three times a week, 5 to 7 ml per ACD-tube, 5 tubes per day, if the number of birth allows such sampling. ABO blood group, hemoglobin electrophoresis, G6PD enzyme activity and Duffy status of the blood will be determined before using reticulocytes for P. vivax invasion and culture.

Data will be entered and processed using Microsoft Excel. Parasitemia will be directly correlated to CQ concentration in blood and will allow categorizing the parasites according to the slope of their clearance time and their sensitivity to CQ.

Statistical analysis will be performed when required to detect any significant effects.

Conditions

Vivax Malaria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Chloroquine

Patients treat with chloroquine sulfate (NIVAQUINE) 10 mg/kg/day - 3 days

Group Type: EXPERIMENTAL

Chloroquine sulfate

Intervention Type: DRUG

Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days

DHA-PP

Patient treat with DHA 40 mg and PP 320 mg, (Duo-Cotecxin®) The approximate total adult dose is 2-4 mg/kg for DHA and 20mg/kg for PP

Group Type: ACTIVE_COMPARATOR

DHA-PP

Intervention Type: DRUG

DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.

Interventions

Chloroquine sulfate

Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days

Intervention Type: DRUG

DHA-PP

DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.

Intervention Type: DRUG

Other Intervention Names

NIVAQUINE; Duo-Cotecxin

Eligibility Criteria

Inclusion Criteria

(i) Being aged 15 years or more with competency to give informed consent, (ii) Being positive for P. vivax and mono-infected

Exclusion Criteria

(i) Being aged 14 years or less (ii) Individuals with illness that affected competency to give informed consent, (iii) Pregnant or lactating women (iv) Having taken antimalarial drugs in the past month

• Minimum Eligible Age: 15 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

Institut Pasteur, Cambodia

OTHER

Sponsor Role: lead

Responsible Party

Didier Menard

Malaria Molecular Epidemiology Unit

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dysoley Lek, MD

Role: PRINCIPAL_INVESTIGATOR

National Centre for Parasitology Entomology and Malaria Control

Didier Ménard, PharmD, PhD

Role: PRINCIPAL_INVESTIGATOR

Institut Pasteur in Cambodia

Jean Popovici, PhD

Role: PRINCIPAL_INVESTIGATOR

Institut Pasteur in Cambodia

Locations

Provincial Hospital

Banlung, Ratanakiri, Cambodia

Countries

Cambodia

References

Popovici J, Friedrich LR, Kim S, Bin S, Run V, Lek D, Cannon MV, Menard D, Serre D. Genomic Analyses Reveal the Common Occurrence and Complexity of Plasmodium vivax Relapses in Cambodia. mBio. 2018 Jan 23;9(1):e01888-17. doi: 10.1128/mBio.01888-17.

Reference Type: DERIVED

PMID: 29362233 (View on PubMed)

Other Identifiers

R01AI103228

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IPC_Pv_CQR_RTK

Identifier Type: -

Identifier Source: org_study_id